2022
DOI: 10.1111/ctr.14772
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS‐CoV‐2 vaccines in solid organ transplant recipients: A case series

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 5 publications
0
1
0
Order By: Relevance
“…The NIH also has a clinical trial underway to study if immune responses to vaccination improve when immunosuppression medication is temporarily reduced in the days leading up to and following vaccination (76,77). Though still unmatched to the general population, as boosters became available in the US, data shows that additional mRNA inoculations increase antibody titers for the majority of solid organ transplant patients (78,79).…”
Section: Vaccination Policies: History Present and Solutions Historymentioning
confidence: 99%
“…The NIH also has a clinical trial underway to study if immune responses to vaccination improve when immunosuppression medication is temporarily reduced in the days leading up to and following vaccination (76,77). Though still unmatched to the general population, as boosters became available in the US, data shows that additional mRNA inoculations increase antibody titers for the majority of solid organ transplant patients (78,79).…”
Section: Vaccination Policies: History Present and Solutions Historymentioning
confidence: 99%